Navigation Links
QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
Date:9/5/2011

GERMANTOWN, Maryland, September 6, 2011 /PRNewswire/ --

- QIAGEN assay for JAK2 V617F mutation aims to identify patients more likely to respond to Lilly's 'JAK2 inhibitor' and to monitor responses to therapy

- Lilly will co-develop companion diagnostic

- QIAGEN's exclusive access to JAK2 biomarker underpins potential future expansion with additional Pharma compounds targeting gene

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

Lilly's proprietary compound, called a JAK2 inhibitor, targets the Janus kinase 2 (JAK2) gene, which has been shown to play a role in myeloproliferative neoplasms, a variety of blood cancers that cause blood cells to grow abnormally.

Under the terms of the agreement, QIAGEN will develop a new companion diagnostic test that will provide both qualitative and quantitative results for JAK2 V617F. The assay is intended to identify patients most likely to benefit from treatment with inhibitors of the pathway. The scope of the partnership includes development and use of the QIAGEN JAK2 assay during clinical trials and also covers manufacturing and joint commercialization of the diagnostic product in parallel with the Lilly compound.

QIAGEN gained exclusive access to the JAK2 biomarker through an agreement with Ipsogen, a French company that is a pioneer in profiling and biomarkers for leukemia and other blood cancers. In June, QIAGEN announced a proposal to fully acquire Ipsogen through a process that is under way. The JAK2 pathway is considered to bring high value to drug development in terms of defining and
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
2. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
3. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
4. QIAGEN Acquires Exclusive Licence for Key PI3K gene
5. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
6. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
7. Plexus Awarded Development Contract With QIAGEN
8. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
9. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
10. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
11. SciQuest Announces Strategic Alliance with QIAGEN
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Barrington, MA (PRWEB) October 25, 2014 ... control products, is pleased to announce the release ... achieve the highest level of contamination containment in ... ISO Class 3 and higher cleanroom environments, ValuSeal® ... filament polyester knit laundered wiper that continues Berkshire’s ...
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ... at the Fourth International Symposium on Thymosins in Health ... "When thymosin beta 4 (TB4) linked ... the peritoneal cavity in a rodent model of stroke, ... the brain parenchyma (the functional tissue of the brain). ...
(Date:10/25/2014)... ... the addition of the  "The Global Market ... Nanomaterials "  report to their offering.  ... graphene are the strongest, lightest and most ... performance-per-weight greater than any other material. In ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... and Rhythm, a biopharmaceutical company, today announced that Actavis ... wholly owned subsidiary, Rhythm Health, Inc., which is developing ... of diabetic gastroparesis and other GI functional disorders. ... trial of relamorelin for the treatment of diabetic gastroparesis ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... 20 years of commercial life sciences sales experience to Cyntellect ... 21 Cyntellect, a privately-held life sciences company leading the ... announced today that it has appointed Andre Lubarsky as the ... responsible for the sales of Cyntellect,s cell purification and cell ...
... LCAV ), a leading provider of laser vision ... of Michael J. Celebrezze,to the position of Chief Financial ... Mr. Celebrezze, who has served as interim CFO since ... as Senior Vice,President of Finance and Treasurer in July ...
... GPRO ),CE-marked APTIMA(R) HPV assay may ... detect high-risk human papillomavirus (HPV) infections that are,associated ... nine,oral presentations and two scientific posters presented last ... conference of the,European Research Organization on Genital Infection ...
Cached Biology Technology:Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America 2LCA-Vision Names Michael J. Celebrezze CFO 2LCA-Vision Names Michael J. Celebrezze CFO 3LCA-Vision Names Michael J. Celebrezze CFO 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 2Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 3Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 4Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting 5
(Date:10/17/2014)... regarding Ebola is critical and pertinent for practicing physicians ... outbreak and epidemic. The Journal, Disaster Medicine and ... Ebola Virus and Public Health, to surround the public, ... critical societal moment. , On October 17, the ... . The primer was prepared by Dr. Eric Toner, ...
(Date:10/16/2014)... wages war on the human body. Battles are ... In pancreatic cancer, this stalemate—known as tumor dormancy—can ... malignant, a phenomena that is poorly understood. ... laboratory of Salvatore Torquato, a Professor of Chemistry ... surrounding tumor dormancy and the switch to a ...
(Date:10/16/2014)... Although monocultures can be cultivated efficiently, they are ... water caused by monoculture cultivation is becoming increasingly ... principal crop form and are regarded as the ... production – quite wrongfully, finds Bernhard Schmid, an ... advocates a novel form of agriculture and forestry. ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... highly detailed study, Tecnalia has calculated the carbon footprint of ... from the field work right up to the end of ... the piece of information that allows one to know the ... has enabled the Grupo Faustino to be the first winery ...
... After outgrowing teenage infatuations with the girl next door, ... amorous attractions to the wife next door, according to ... testosterone levels dropped when they were interacting with the ... mechanisms that keep men from constantly competing for each ...
... (ACMG) released the widely-anticipated "ACMG Recommendations for Reporting of ... at its 2013 Annual Clinical Genetics Meeting today in ... one of the largest gatherings of medical and health ... and genome sequencing become more commonly used in medical ...
Cached Biology News:Tecnalia has calculated the carbon footprint of some wines 2Men may have natural aversion to adultery with friends' wives 2ACMG releases report on incidental findings in clinical exome and genome sequencing 2ACMG releases report on incidental findings in clinical exome and genome sequencing 3
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Rabbit polyclonal to MAP3K12 ( Abpromise for all tested applications). Antigen: Synthetic peptide conjugated to KLH from the C-terminal region of human MAP3K12 Entrez Gene ID: 7786 Swiss ...
Mouse monoclonal [SIT-01] to SIT ( Abpromise for all tested applications). entrezGeneID: 27240 SwissProtID: Q9Y3P8...
Anti-MMP-25 (Membrane-type MMP-6, Mt6MMP), hinge region; rabbit host...
Biology Products: